Cargando…
Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
Between 20% and 50% of cardiovascular patients treated with clopidogrel, an anti‐P2Y12 drug, display high on‐treatment platelet reactivity (HTPR) and are not adequately protected from major adverse cardiovascular events (MACE). Despite a minor influence of the CYP2C19*2 genetic variant on the pharma...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647256/ https://www.ncbi.nlm.nih.gov/pubmed/23537811 http://dx.doi.org/10.1161/JAHA.112.000131 |